Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with …
D Serra, YL He, J Bullock, GJ Riviere… - … journal of clinical …, 2008 - europepmc.org
Background Vildagliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4) that
improves glycemic control and pancreatic b-cell function in patients with Type 2 diabetes …
improves glycemic control and pancreatic b-cell function in patients with Type 2 diabetes …
Vildagliptin
S Henness, SJ Keam - Drugs, 2006 - Springer
Abstract▴ Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is being evaluated in
the treatment of patients with type 2 diabetes mellitus. It improves glycaemic control by …
the treatment of patients with type 2 diabetes mellitus. It improves glycaemic control by …
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
B Richter, E Bandeira-Echtler… - Vascular health and …, 2008 - Taylor & Francis
Background: In type 2 diabetes mellitus (T2DM) there is a progressive loss of β-cell function.
One new approach yielding promising results is the use of the orally active dipeptidyl …
One new approach yielding promising results is the use of the orally active dipeptidyl …
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers
YL He, B Flannery, J Campestrini, S Leon… - … medical research and …, 2008 - Taylor & Francis
Objective: Vildagliptin is an orally active, potent and selective DPP-4 inhibitor that improves
glycemic control in patients with type 2 diabetes by increasing alpha-and beta-cell …
glycemic control in patients with type 2 diabetes by increasing alpha-and beta-cell …
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
YL He, R Sabo, GJ Riviere, G Sunkara… - … medical research and …, 2007 - Taylor & Francis
Objective: Vildagliptin is a potent and selective dipeptidyl peptidase‑IV (DPP‑4) inhibitor that
improves glycemic control in patients with type 2 diabetes by increasing alpha and beta-cell …
improves glycemic control in patients with type 2 diabetes by increasing alpha and beta-cell …
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
YL He, D Serra, Y Wang, J Campestrini… - Clinical …, 2007 - Springer
Background Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under
development for the treatment of type 2 diabetes mellitus. Objectives To assess the …
development for the treatment of type 2 diabetes mellitus. Objectives To assess the …
Vildagliptin inhibits high fat and fetuin-A mediated DPP-4 expression, intracellular lipid accumulation and improves insulin secretory defects in pancreatic beta cells
S Nag, S Mandal, O Mukherjee, T Majumdar… - … et Biophysica Acta (BBA …, 2024 - Elsevier
Abstract Dipeptidyl peptidase-4 (DPP-4), a ubiquitous proteolytic enzyme, inhibits insulin
secretion from pancreatic beta cells by inactivating circulating incretin hormones GLP-1 and …
secretion from pancreatic beta cells by inactivating circulating incretin hormones GLP-1 and …
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers
YL He, R Sabo, J Campestrini, Y Wang… - British journal of …, 2008 - Wiley Online Library
What is already known about this subject• Vildagliptin is a new, potent, and selective
inhibitor of DPP‐4.• The efficacy and safety of vildagliptin in type 2 diabetes has been …
inhibitor of DPP‐4.• The efficacy and safety of vildagliptin in type 2 diabetes has been …
Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population
A Schweizer, S Dejager, JE Foley… - Diabetes, Obesity …, 2010 - Wiley Online Library
Aim: To assess the cardiovascular and cerebrovascular (CCV) safety of the dipeptidyl
peptidase‐IV inhibitor vildagliptin. Methods: Data were pooled from 25 Phase III studies of …
peptidase‐IV inhibitor vildagliptin. Methods: Data were pooled from 25 Phase III studies of …
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
A Schweizer, S Dejager, JE Foley… - Vascular Health and Risk …, 2011 - Taylor & Francis
Aim: Analyzing safety aspects of a drug from individual studies can lead to difficult-to-
interpret results. The aim of this paper is therefore to assess the general safety and …
interpret results. The aim of this paper is therefore to assess the general safety and …